関連情報 : Ipilimumab - バイオマーケットjp

「Ipilimumab」に関連した情報

バイオ掲示板更新情報

バイオ掲示板更新情報 Former President Jimmy Carter, 91, Claims to Be Cancer-Free After Treatment for Metastatic Melanoma; Merck’s New Immunotherapy Drug KEYTRUDA Given Major Credit for Good Initial Result
... kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. read more
バイオ掲示板更新情報 Pioneer in Cancer Immunotherapy Receives 2015 Lasker-DeBakey Award; Nation’s Highest Award for Clinical Medical Research Goes to MD Anderson's Jim Allison for Seminal Work Leading to Development of Melanoma Drug Ipilimumab
For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., Chair of Immunology at The University of Texas MD Anderson Cancer Center, has been awarded the nation’s highest honor for clinical m
バイオ掲示板更新情報 Exosome-Based Platform Can Enrich for Cancer-Specific Exosomes; New Data Demonstrates mRNA Signature in Exosomes Derived from Metastatic Melanoma Patients Treated with Ipilimumab; Early Signature Changes Associated with Improved Progression-Free Survival
... tled, “Early Exosome mRNA Changes Are Associated with Improved Progression-Free survival of Metastatic Melanoma Patients on Ipilimumab: Identification of a Novel Exosome mRNA Signature of Ipilimumab Response.” “These data are quite exciting, as ...
バイオ掲示板更新情報 Exosome Diagnostics to Present New Data on Plasma EGFR Mutation Detection Using a Combined Exosomal RNA and Circulating Tumor DNA Approach & on D of Novel Exosome mRNA Signature of Ipilimumab Response in Metastastic Melanoma Patients
... er is “Early Exosome mRNA Changes Are Associated with Improved Progression-Free Survival of Metastatic Melanoma patients on Ipilimumab: Identification of a Novel Exosome mRNA Signature of Ipilimumab Response” (#LB-C05). This poster will be present ...
バイオ掲示板更新情報 Cell Article Analyzes How Much Time & Effort Are Involved in Development of Important Therapeutic Drugs—7,000 Scientists, 5,700 Institutions, 100 years in One Typical Example; Analysis of “Elite Performers” May Accelerate Progress
... ely mapped the discovery path to two drugs that have recently been approved by the FDA and could be characterized as "cures"--ipilimumab for certain forms of cancer and ivacaftor for cystic fibrosis. The researchers relied on citations from published ...

すべて表示
運営会社:バイオアソシエイツ株式会社

バイオマーケットjpは、ライフサイエンス研究者・バイオビジネス関係者のための会員制サイトです。

ユーザー登録すると...

コンテンツの全文表示・コメント投稿・各種お申し込み・ダウンロード等、

様々なユーザー専用機能をご利用いただくことができます。

 

ユーザー登録は1分で完了

ユーザー登録は無料

運営者:バイオアソシエイツ株式会社

登録ユーザー数
2904人
2018年01月23日 現在
38 人のユーザが現在オンラインです。 (1 人のユーザが 関連情報 を参照しています。)
登録ユーザ: 0 ゲスト: 38
アクセスカウンター
DATEVisits/PVs
2018/01/23:290/1086
2018/01/22:776/16443

 

クリエイティブ・コモンズ・ライセンス
バイオマーケットjpのコンテンツは クリエイティブ・コモンズ 表示 - 非営利 - 改変禁止 4.0 国際 ライセンスの下に提供されています。引用される場合は出典元リンクの記載をお願いします。